Peter Rankin and Andrew Tepperman published an article entitled “Biosimilars: economics and intellectual property,” which appeared in IPPro Life Sciences. The article discusses new challenges and opportunities innovators face relating to their IP rights with the onset of biosimilars. To read the article, click the link below.
Navigating the evolving landscape for psychedelic therapies
These substances may offer innovative treatment options for psychiatric conditions including PTSD, major and treatment-resistant depression, generalized...